ADMA Biologics ADMA Accounts payable and other current liabilities
Accounts payable and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's accounts payable and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's accounts payable and other current liabilities?
- ADMA Biologics (ADMA) reported accounts payable and other current liabilities of $162K in Q1 2026.
- How has ADMA Biologics's accounts payable and other current liabilities changed year-over-year?
- ADMA Biologics's accounts payable and other current liabilities decreased by 83.6% year-over-year, from $985K to $162K.
- What does accounts payable and other current liabilities mean?
- The net change in the company's short-term obligations to suppliers and other accrued expenses during the reporting period. A positive change indicates an increase in liabilities, which serves as a source of operating cash flow, while a negative change indicates the settlement of these obligations.